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Al~straet 
We have investigated the ability of alveolar epithelial cells (human A549 ce11 line and rat type-t1 pneumocytes) toproduce ~l-antitrypsin (AAT). 
Northern blot analysis demonstrated the presence of an ANT-specific mRNA transcript in A549 ceiis. Unstirnuiated A549 ceils secreted in~2munoreac- 
tire AAT at a rate of 0.51 + 0.04 ng/106 cellslh, with a modified glycosyiation compared to serum AAT. AAT formed a complex with neutrophil 
eiastase. Rat type-II pneumocytes secreted in~mnoreactlve AAT Our resuks suggest that alveolar epitheIiai ceils could participate in antiprotease 
defense within the iung through locai AAT production. 
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1. Introduction 
Human ~1-antitrypsin (AAT) is a 54 kDa glycopro- 
tein which consists of a singie polypeptide chain of 394 
amino acids containing about 12% glycans [i]. 
The hepatocyte is considered as the primary source of 
serum AAT [2-4]. Other cell types have been shown to 
synthesize AAT in vitro: human blood monocytes [5], 
pulmonary alveolar and breast milk macrophages [6], 
polymorphonuclear neutrophils [7], activated lympho- 
cyrus [81 and the human intestinal epithelia1 ce11 !ine 
Caco2 [9]. 
Current concepts suggest that AAT constitutes the 
main inhibitor of serine proteases in human and espe- 
cially of neutrophil eiastase and that it plays a key role 
in lung homeostasis. Particuiariy, AAT deficiency has 
been linked with the development of pu!rnonary emphy- 
sema, a disease caused by an imbalance between pro- 
teases and protease inhibkors [10]. 
Interestingly, inves~zigation i to the local sources of 
AAT synthesis within the human lung have focused ex- 
clusively on the contribution of the alveolar macrophage. 
The potential contribution of other major lung cell pop- 
ulations, such as epithelia! cells, to the local production 
of AAT has not been exp!ored. Because type-II pneu- 
mocytes isolated from human lung are not easily availa- 
ble, we have investigated the abiiity of the A549 ceil line 
to synthesize and secrete AAT. This ceil line is derived 
from a patient with iung carcinoma [11~ and has been 
used as a model of human alveolar type-II pneumocytes 
[12]. In addition, we have evidence for AAT secretion by 
rat alveotar type-H pneumocytes in primary culture. 
Thus, this study should provide the foundation ~br 
*Corresponding author. Fax: (33) (!) 40 25 88 50. 
future investigations into the contribution of lung resi- 
den~ ceils to the regu!ation of the iocal antiprotease-host 
defense. 
2. Materials and methods 
2.1. Reagents 
Ham's F12 med'mrn was purchased from Eurobio (Les Ulis, France). 
Fetal calf serum (FCS) was from Gibco (Cergy-Pontoise, France). 
Phenyimethyisuifonylfluoride (PMSF) and lenpep~in were from Sigma 
(La Verpilli6re, France). Endo-fl-acetylglucosaminidase-H (EC
3.2.1.96) (Stre~tomyces plicams) (Endo-H) was from Genzyn~e (Boston, 
MA), peptide-Nt(?v--acetyi-fl-gl=acosaminyt), asparagine amidase F (EC 
3.2.2.18) (Flavobacterium eningosepticum) (N-glycanase) was from 
Boehringer (Meylan, France), endo-c'~-N-acetylgalactesaminidase (EC 
3.2.1.97) (Streptococcus' yneumoniae) (O-glycanase) was from Oxford 
GlycoSystems (Oxford, UK) and neuraminidase (EC 3.2.1.18) (~brio 
&olerae) was from Sigma. Nitroce!iulose membrane (0.45 ym) was 
from Bio-Rad (r, vry/Seine, France), rabbit anti-human AAT antiserum 
was from Boehringer, donkey anti-rabbit IgG antibody conjugated to 
horseradish peroxidase, Hybend N nyion filter and Enhanced Chercd- 
Daminescent (ECL) substrate were from Amersham (Les Uiis, France). 
RNAzol was from Bioprobe (Montreuil/bois, France). Rabbit anti-rat 
AAT antibodies were a gift from Dr. C. Ganthier (Tours, France). 
2.2. Cell culture 
A549, the human lung epithelia1 cell line (CCL 185), was purchased 
from American Type Culture Colicction (Rockville, MD, USA). Ceils 
were cultured in 75 cm 2 flasks in Ham's F12 culture medium containing 
100 mM L-glutamine, 100 U/m1 penicillin, 50 Cram1 streptomycin (com- 
plete medium) supplemented with 15% FCS until the ceils reached 
confluency, and kept at 37°C in a humidified incubator with 5% CO2 
in air. To coilect serum-~qee conditioned medinm, A549 confluent cells 
(9 x 106 cells/flask) were rinsed three times with sterile saline and cut- 
tared in i0 ml FCS-;2"ee comptete medium. Cuhures were re-fed every 
12 h period for 60 h. The supernatants collected on the firs+~ 12 h were 
discarded, while subsequent harvests were collected, centrifuged 
(400 x g for 10 rain) and stored at -20°C after addition of protease 
inhibkors (4 mM PMSF, 40 mM teupeptin). Then ceils were either 
s-~abmitted o a trypsin treatment and washed to allow their numeration 
or frozen in nitrogen before RNA study. 
Type-II pneumocytes were isolated from rnaie Sprague-Dawley rat 
iungs and type-Ii pne~mocytes monoiayers were used 24 h after adhe- 
sion, as previous!y described [I3]. AAT secretion i  type-II pneumocyte 
supernatants was studied over a 24 h period. Supernatants and cells 
were coiiected as described for A549 ceils. 
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2.3. Protein assays 
Total protein was measured by the method of Bradford [14] and AAT 
sapernatants levels by an ELISA as described elsewhere [15]. 
2.4. Enzymatic procedure 
Before ;;he enzymatic procedure (neuraminidase tr atment excepted), 
AAT was denatured by boiling cell culture supernatant for 5 rain in the 
presence of 0.1% SDS and 1% fi-mercaptoethanol. SDS was next neu- 
tralized by Triton X-100 (10-fold excess). Enzymatic treatments were 
performed at 37°C for 24 h in a total volume of i00 .u!. Endo-H was 
used in 50 mM sodium citrate, pH 5.0, at a concentration of 40 U/i; 
N-glycanase in 0.2 M sodium phosphate, pH 8.6, 13 mM EDTA at 
20 U/m1; O-glycanase in 100 mM sodium citrate-phosphate, pH 6.0, 
I00 yg/ml bovine serum albumin at 3 L-/1; neuraminidase in 50 mM 
sodium acetate, pH 5.5, 1 mM calcium chloride at 10 U/1. 
2.5. Western blot analysis 
Samples were su~ected to 9% SDS-PAGE according to Laemmli et 
al. [I@ Protein electrotransfer onto a nitroceliulose membrane was 
performed according to Towbin etal. [t7]. Incubation dine of the 
following steps was 1 h at room temperature and diIafion buffer was 
20 ruM Tris-HC1, 0.5 mM NaCI, 0.1% Tween 20, pH 7.5. Nitrocellulose 
was blocked by irrLmersion i  10% (w/v) non-fat dried miik. Human and 
rat AAT bands were detected with a i : 1,000 dilution of rabbit specific 
anti-corresponding AAT antibodies foliowed by a I : 5,000 dilution of 
donkey anti-rabbit IgG antibodies conjugated to horseradish peroxi- 
dase. Western biots were developed by ECL. 
2.6. Assay of elastase-binding aetivit?/ of human AA T 
50 fll of A549 cell line supernatant and serum containing 60 ng AAT 
were incubated wi~h an equa! volume of human neutrophil ysa~;e elas- 
tase-containing solution. The elastase activity of the so!ation was ~09 
U/1 when measured with a synd~edc substrate [18]. Incubation was 
carried out for 2 h at room temperature under continuous tirring 
Then, the mixture was ana ysed by Western blotting. 
2. 7. Detection of human AAT mRNA 
The A549 col1 Iine was evaluated for the presence of AAT mRNA 
transcripts using Northern biot analysis. Total ceilu!ar RNA was ex- 
tracted from A549 celis and HepG2 cells using the RNAzoi procedure 
[19]. 10 ,ug of total RNA were subjected to i% agarose-formaldehyde 
gel eiectrophoresis and transferred to nyion filters [2(I]. Filters were 
hybridized with a ~2p-iabeiled full-iength cDNA probe specific for 
human AAT i2i]. 
2.8. Data analysis 
All data are expressed as the mean + S.E.M. 
3. Restfits 
3.1. ~Uuman AAT secretion by A549 cells 
3.1.i. Characterfzation Secretion o f ,~_T  by A549 ce~s 
was quai i tat ive ly  demonst ra ted  by v isual izat ion o f  the 
Western Not  o f  a un ique 59 kDa band revealed by spe- 
cific ant ibod ies  against  human AAT (Fig. 1). This  un ique  
band had a di f ferent e lect rophoret ic  mobi l i ty  compared  
to the human serum AAT (54 kDa) .  
3.1.2. @can structural approach o f AAT In o rder  to 
invest igate the difference o f  apparent  molecu lar  mass  
between human ser~rn AAT  and  A549-secreted AAT,  
A549 culture supernatants  and d i luted serum were sub- 
mi t ted  to di f ferent glycosidase t reatments  fo l lowed by 
Western Not .  A f ter  N-g lycanase t reatment ,  a part ia i  de- 
g lycosytadon o f  AAT  was obta ined  (F ig I). Indeed,  four  
bands were observed cor respond ing  to nat ive AAT  and 
AAT with one, two or three miss ing N-g lycan chains, 
s~aggesting the presence o f  three N-g lycan chains in 
A549-secreted AAT,  s imi lar to serum AAT.  Moreover ,  
tota l ly  deglycosy lated AAT,  cor respond ing  to the pol-  
ypept ide chain,  was approx imate ly  i kDa  heavier  than 
serum AAT (Fig. ~j. Neuramin idase  t reatment  o f  A549 
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F ig . .  Western blot analysis of A549 ceil supernatant and human serum AAT before and after incubation with g!ycosidases (N-glycanase and
aeuraminidase) and human neutrophii eiastase. AAT bands were visualized by immuno-detection using enhanced chemiluminescence as described 
in section 2. 
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cell supernatants and human serum !ed to a 55 and a 52 
kDa AAT band, respectively. The difference of apparent 
molecular mass between ative and desialylated protein 
was higher for A549 AAT than tbr serum AAT, indicat- 
ing an increased sialylation of giycans chains of A549 ce11 
!ine AAT (Fig. 1). O-Glycanase and Endo-H treatment 
had no effect on A549-secreted AAT, excluding the pres- 
ence of O-gIycans and of high-mannose or hybrid type 
N-glycans on the protein (data not skown). 
3.1.3. )~iologicai activiCv of AAT  After incubation of 
A549 cell ine supernatan~ and serum with haman neu- 
trophil eiastase, Western blot analysis detected an .~kT 
elastase complex with an apparent molecular mass of 76 
and 78 kDa for A549 celt line and serum AAT~ respec- 
tively (Fig. 1). The presence of uncomplexed AAT is 
presumably due to SDS-induced issociation of the com- 
plexes [22]. No band was revealed when elastase was 
incubated with fresh cahure medium (data not shown). 
3.1.4. Quantification of secreted AAT Secretion of 
AAT and total proteins was 0.51 + 0.04 ng/106 cells/h 
and 0.79 + 0.03/2g/106 cells/h (n = 6), respectively, and 
did not significantIy vary in the course of~he 48 h period. 
Thus, AAT secretion represented 0.06% of total proteins 
secreted. 
3.1.5. AAT  mRNA in A549 cells' When total cellular 
RNA from human A549 was suNected to Northern blot 
analysis with radiolabeled human AAT cDNA as a 
probe (Fig. 2), a singie 1.60 kb specific AAT mRNA 
band was present in A549 cells. It was identical in appar- 
enr. size to that detected in the HepG2 ce11 line used as 
a control. 
3.2. Rat AAT  secretion b), type-Il pneumocytes 
Type-It pneumocytes in primary cu!ture secreted ira- 
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Fig. 2. Detection of AAT mRNA in A549 cells, l0 ¢tg of total cellular 
RNA isolated from HepG2 cells (lane 1) and L-ore A549 cells (lane 2) 
were s:abjected to Northern blot anaiysis with human ,~T  cDNA as 
probe. Molecular mass markers (lane 3) (t .60 kb AAT mRNA tran- 
script indicated). 
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Fig. 3. Western blot anaiysis of rat serum (iane i) and rat type-H 
pnetamoeytes supernatant (lane 2) AAT after visualization by in~-nuno- 
detection using enhanced chemiluminescence as described in section 2. 
munoreactive AAT, as observed on Western blot 
(Fig. 3). A single band with an increased apparent moiec- 
ular mass (59 kDa) compared to rat serum AAT (54 
kDa) was detected. 
4. Discussion 
Protease inhibitors are thought o be important in 
regulating proteases produced by inflammatory cells, 
such as neutrophiis or monocytes, during inflammation. 
These proteases can be detrimentai to the connective 
tissue and have been implicated in the pathogenesis of
lung emphysema. AAT, one of ~:he main protease inhib- 
kors in the iung, is mainly produced by the iiver. How- 
ever, 1ocai extrahepatic synthesis has been ascribed to 
alveolar macrophages [6]and neutrophils [7]. in the pres- 
ent work, we show that AAT is expressed and secreted 
in an unstimulated human pulmonary epitheiial-derived 
cell line, the A549 cell line. Furthermore, we show that 
rat type-II pneumocytes in primary culture spontane- 
ousiy secrete AAT. Taken together, our results indicate 
that alveolar epithelial cells could participate to the anti- 
protease defense within the lung ~hrough AAT produc- 
tion. 
The apparent size of human AAT rnRNA is identical 
to that in the human hepatoma ceil line [23]. Western 
Not anaiysis of A549-secreted A,~F demonstrates a 
unique band with a greater apparent molecular mass 
compared to human serum AAT. The observed iffer- 
ence could be dee to a modifed polypeptide chain. How- 
ever, the main difference is a result of modified glycosyl- 
ation of A549 AAT. Taking together ~he results of the 
glycosylation study, A549 AAT shares with serum AAT 
(of hepatic origin, essentially) the presence of three N- 
174 
glycan chains of  complex type and the absence of any 
O-g!ycan or high-mannose or hybrid N-glycan chains. 
Our  data suggest, however, that serum and A549 cei! 
AAT differ by the presence of hypersiaIyiated and highly 
branched chains in the la:ter. Instead of producing AAT 
tha: contains one tri- and two bi-antennary side chains 
(as occurs in the liver), A549 processing of  AAT may 
result in tri- and/or tetra-antennary sialylated side 
chains, which suggests a specific glycosyltransferase ac- 
tion. Such high:y branched chains have already been 
observed in A,~t" isolated from human hepatoma cell 
lines [3,4] and from various adenocarcinoma ceil iines 
[24]. 
We examined the bio!ogical activity of  AAT synthe- 
sized by A549 celis. AAT secreted by A549 cells forms 
a complex with neutrophil elastase, as does serum AAT, 
although their glycosylation pattern is different. This 
result confirms the absence of involvement of  glycan 
chains in the biological anti-elastase activity of  AAT. 
This is in accordance with previous studies in which 
unglycosylated recombinant human AAT,  as we11 as ab- 
norn~ai AAT secreted by the human hepatoma ce11 line 
PLCfPRF/5 [4], were found to be functionally active as 
protease inhibitors [25]. 
Measurements concerning levels of  A 549 cell secre- 
tion were pertbrmed over a 48 h period. Daring this 
incubation period, AAT and total protein secretion was 
constant. AAT secretion is tow compared to human 
hepaWcyte cell tines [3] and adherent blood monocytes 
[26]. AAT represented 0.06% of the secreted proteins by 
the A549 cel! iine, which is simiiar to that of  mucus 
protease inhibitor (MPt) (0.1%), and higher than that o f  
e!afin (0.004%), two other protease inhibitors secreted by 
A549 cells [12]. 
in conclusion, we demonstrate that, in vitro, alveolar 
epithelial cells secrete AAT. This suggests that, even if 
hepatocytes remain the primary source of  AAT in the 
body, aiveo!ar epithelial cells couid participate in vivo in 
the local antiprotease screen in the alveo!ar space. 
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